Anastrozole
Arimidex · ZD-1033 · Adex · A-dex
Last updated
At a glance
Overview
Anastrozole — branded Arimidex and widely called "adex" — is the community's default tool for keeping estradiol in check on aromatizing cycles. It's a non-steroidal type II aromatase inhibitor that blocks the conversion of testosterone to estrogen, which is exactly what is desired when bloat, nipple sensitivity, or creeping blood pressure show up on a moderate-to-heavy test cycle.
The reason it's earned its spot in nearly every serious PED user's cabinet comes down to precision. A long ~48-hour half-life means twice-weekly dosing holds steady levels, pharma tabs are cheap and easy to quarter, and the dose-response is predictable enough that you can titrate against sensitive E2 bloodwork instead of guessing. On TRT, it can rescue a protocol where estrogen has drifted high; on blast, it prevents gyno and water retention without the ER-tissue coverage of a SERM.
"Aromatase inhibition with anastrozole increased serum testosterone and decreased serum estradiol concentrations, roughly doubling total T and lowering E2 by about 50%." — Leder et al., JCEM (2004)
The catch — and the reason the modern consensus has shifted away from auto-dosing an AI with every cycle — is that over-suppressing E2 is its own disaster: dead libido, flat mood, dry joints, and a worse lipid profile than the AAS alone would produce. Used correctly, anastrozole is a scalpel. Used blind at oncology doses, it's a sledgehammer to one's cycle.
In this guide we'll cover anastrozole dosage across TRT, moderate, and blast cycles, how to build a PCT-adjacent protocol (and when to skip the AI entirely in favor of a SERM), the side effects worth actually tracking, and how it compares to alternatives like exemestane, raloxifene, and tamoxifen.
How Anastrozole works
Competitive Inhibition of CYP19A1 (Aromatase)#
Anastrozole is a reversible, non-steroidal type II aromatase inhibitor in the triazole class. It works by reversibly binding to the heme iron at the active site of CYP19A1 — the aromatase enzyme — blocking the conversion of androgens (testosterone, androstenedione) into estrogens (estradiol, estrone). Because the binding is reversible and non-covalent, recovery of aromatase activity tracks drug washout rather than requiring new enzyme synthesis, which is the key mechanistic contrast with exemestane (a suicide inhibitor that permanently deactivates the enzyme).
At 1 mg/day in men, whole-body aromatization is suppressed by roughly 96–97%, driving serum estradiol down and letting unaromatized testosterone accumulate.
"Aromatase inhibition with anastrozole increased serum testosterone and decreased serum estradiol concentrations, roughly doubling total T and lowering E2 by about 50%." — Leder BZ et al., Journal of Clinical Endocrinology & Metabolism, 2004
For the PED user, this is the load-bearing mechanism: less conversion of your exogenous test to E2 means less bloat, less gyno risk, less estrogen-mediated blood pressure creep, and a cleaner visual result on cycle.
Disruption of Hypothalamic Negative Feedback#
Because estradiol — not testosterone — is the dominant negative-feedback signal at the hypothalamus and pituitary in men, lowering E2 increases endogenous LH and FSH output. This is why anastrozole raises natural testosterone in hypogonadal or borderline-low men without any exogenous androgen.
"Coadministration of anastrozole maintained testosterone within the therapeutic range significantly longer and kept estradiol levels in range compared with placebo." — Dias JP et al., Journal of Sexual Medicine, 2014
Practically, this means anastrozole has two distinct use-cases driven by the same mechanism: (1) on-cycle, it controls E2 from your exogenous test, and (2) in TRT or secondary hypogonadism, it can nudge the HPTA to produce more of its own T by removing the estrogen brake. It is not a PCT drug in the SERM sense — it doesn't block ER at the pituitary, it just lowers the ligand — which is why modern PCTs lean on clomid/enclomiphene/nolva instead.
Tissue-Level Estrogen Suppression#
Aromatase isn't just gonadal — it's expressed in adipose tissue, muscle, brain, bone, and breast tissue. Anastrozole suppresses aromatization systemically, which is why it works on gyno (breast-tissue aromatase), reduces water retention (lower E2-driven aldosterone/ADH activity), and why over-suppression has real downstream cost on joints, lipids, libido, and bone.
"Arimidex (anastrozole) was found to be a potent inhibitor of aromatase activity, with a high selectivity and a long duration of action allowing convenient once-daily dosing." — Plourde PV et al., Breast Cancer Research and Treatment, 1994
The selectivity matters: anastrozole doesn't meaningfully inhibit cortisol or aldosterone synthesis (unlike first-generation AIs like aminoglutethimide), so adrenal function stays intact. The "side effects" people complain about are almost always downstream of over-suppressing E2 itself, not off-target enzyme inhibition.
Why E2 Floors Are a Problem (The Other Half of the Mechanism)#
The same mechanism that prevents gyno causes every anastrozole horror story when over-dosed. Estradiol is not a "female hormone" you want to zero out — in men it regulates HDL, bone turnover, joint synovial fluid, libido circuitry, and endothelial NO signalling. Crash E2 and you crash all of it.
"Estrogen suppression with anastrozole adversely affected lipid profiles and resulted in decreased HDL cholesterol, highlighting the importance of not over-suppressing estradiol." — Mauras N et al., Journal of Clinical Endocrinology & Metabolism, 2000
This is why modern protocols target a sensitive-assay E2 of roughly 20–40 pg/mL, not the lowest possible number. The community mantra — "estrogen is your friend, manage it, don't kill it" — is a direct consequence of this mechanism.
Pharmacokinetic Consequences for Dosing#
The ~46–50 hour half-life and ~85% oral bioavailability mean anastrozole accumulates to steady state over about a week, and plasma levels at steady state sit roughly 3–4× the single-dose value. Translation: low, infrequent dosing still produces stable aromatase inhibition, which is why twice-weekly 0.25–0.5 mg protocols work as well as they do.
| Dose pattern | Context | Mechanistic rationale |
|---|---|---|
| 0.125–0.25 mg 2×/wk | TRT (100–200 mg test/wk) | Minimal aromatase load; steady-state low-level inhibition |
| 0.25–0.5 mg 2×/wk | Moderate cycle (400–600 mg test/wk) | Matches aromatization rate of moderate T doses |
| 0.5 mg EOD | Heavy/aromatizing blast | Higher substrate load needs more frequent inhibition |
| 1 mg/day | Gyno rescue (short-term) | Maximal aromatase suppression for 3–7 days, then taper |
The long half-life also explains why abrupt discontinuation mid-cycle causes an estrogen rebound 5–7 days later as the enzyme pool recovers faster than exogenous test clears — taper, don't cliff-drop.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 0.125–0.25 mg | Twice weekly | Documented entry-level range |
| Mid | 0.25–0.5 mg | Twice weekly | Most commonly studied range |
| High | 0.5–1 mg | Twice weekly | Long half-life supports twice-weekly dosing at steady state. Common pattern: dose with injection days (e.g., Mon/Thu). Heavy aromatizing cycles may need EOD or daily; TRT often needs 1×/wk or nothing at all. Titrate to sensitive E2 bloods, not guesswork. |
Cycle length & outcomes
Documented cycle
4–16 weeks
Plateau after
16 wks
Cycle Length & Dose by Goal#
Anastrozole isn't cycled in the traditional sense — it's titrated. You run it as long as you're running an aromatizing compound, at the lowest dose that keeps sensitive-assay E2 in the 20–40 pg/mL range. The long half-life (~46–50 h) means you don't need daily dosing; twice-weekly with injection days hits steady state cleanly.
| Goal / Context | Cycle Length | Dose |
|---|---|---|
| TRT adjunct (100–200 mg test/wk) | Ongoing, PRN | 0.125–0.25 mg 1–2×/week |
| Moderate cycle (400–600 mg test/wk) | Duration of aromatizing compound | 0.25–0.5 mg 2×/week |
| Heavy blast (750 mg–1 g test/wk, or test + dbol/drol) | Duration of cycle | 0.5 mg EOD, titrate to bloods |
| Acute gyno flare (early, itchy nipple) | 3–7 days knockdown, then maintenance | 1 mg/day → 0.5 mg EOD |
| Established gyno lump | 4–8 weeks (pair with SERM) | 0.5–1 mg/day + raloxifene 60 mg/day |
Loading, Tapering & Onset#
No loading phase. Steady state builds naturally over ~7 days with the 46–50 h half-life, and plasma levels accumulate to roughly 3–4× single-dose values. Front-loading is unnecessary and a reliable way to crash E2 before your first bloodwork.
"Arimidex (anastrozole) was found to be a potent inhibitor of aromatase activity, with a high selectivity and a long duration of action allowing convenient once-daily dosing." — Plourde et al., Breast Cancer Research and Treatment (1994)
Onset. Symptomatic relief from estrogenic bloat, nipple sensitivity, and puffiness usually appears within 3–5 days. Leder's RCT showed 1 mg/day roughly halved E2 and doubled total T in men — a dramatic shift you'll feel, which is exactly why most PED users need far less than 1 mg/day.
"Aromatase inhibition with anastrozole increased serum testosterone and decreased serum estradiol concentrations, roughly doubling total T and lowering E2 by about 50%." — Leder et al., Journal of Clinical Endocrinology & Metabolism (2004)
Taper off, don't yank. Stopping anastrozole cold mid-cycle triggers an estrogen rebound 5–7 days later as aromatase activity recovers against still-elevated androgen substrate. When coming off an aromatizing cycle, drop the dose in half for the final week rather than quitting abruptly. If transitioning into PCT, most modern protocols drop the AI entirely — SERMs (nolva, clomid, enclomiphene) do the HPTA-restart work, and suppressing the very estrogen signal driving LH normalization is counterproductive.
Bloodwork Cadence#
This is the non-negotiable part. Anastrozole dosing without bloods is guesswork, and the community's most consistent mistake is dosing to "feel" and crashing E2.
| Timepoint | Panel |
|---|---|
| Pre-cycle baseline | Sensitive E2 (LC-MS/MS), total + free T, SHBG, CBC, CMP, lipids |
| Week 4 of cycle | Sensitive E2, total + free T, lipids |
| Every 8–12 weeks on blast | Sensitive E2, total + free T, lipids, CMP |
| 2 weeks after dose change | Sensitive E2 to confirm landing zone |
Always order sensitive (LC-MS/MS) estradiol, not standard immunoassay — the standard assay cross-reacts and reads falsely high in men, and people chase phantom numbers with extra anastrozole.
"Estrogen suppression with anastrozole adversely affected lipid profiles and resulted in decreased HDL cholesterol, highlighting the importance of not over-suppressing estradiol." — Mauras et al., Journal of Clinical Endocrinology & Metabolism (2000)
That lipid shift is the hidden cost of overdoing it — on top of the AAS-driven HDL hit you already have.
Anastrozole vs Alternatives#
- vs Aromasin (exemestane): Aromasin is a suicide (irreversible) AI; it covalently binds aromatase, so rebound is gentler and it has a mildly androgenic metabolite. Anastrozole is cheaper, more predictable at low doses, and easier to titrate — which is why it remains the default. Don't run both simultaneously.
- vs Letrozole: Letro is a sledgehammer (~98%+ suppression at 2.5 mg). Reserve it for aggressive gyno rescue, not routine E2 management — the crash risk is much higher.
- vs SERMs (nolva, ralox) for gyno: AIs prevent; SERMs treat. For an established lump, a SERM outperforms any AI because it antagonizes ER directly at breast tissue. An AI alone won't regress fibrotic gyno.
Run it low, dose it to bloods, and accept that a healthy male PED user almost never needs the 1 mg/day oncology dose. The community consensus has shifted hard in the last decade — most users on moderate test cycles do better with no AI or a minimal 0.125–0.25 mg 2×/week than with the old "0.5 mg EOD standard" that crashed half the forum a decade ago.
Risks & mistakes
Common (most users)#
- E2 crash symptoms at too-high a dose — lethargy, dead libido, soft erections, dry/cracking joints, loss of pumps, insomnia, low mood. This is the #1 anastrozole side effect and it's almost always a dosing error. Drop the dose by half, skip the next one or two doses, and retest sensitive E2 before resuming. Target 20–40 pg/mL, not "as low as possible."
- Headaches — usually mild and linked to rapid E2 drops. Hydrate, cut dose, and let levels stabilize.
- Hot flashes / flushing — more common in the first 1–2 weeks as E2 settles. Resolves on its own or with a lower dose.
- Mild GI upset (nausea, loose stool) — take with food. Uncommon at PED doses; seen more at 1 mg/day.
- Joint stiffness / reduced joint lubrication — a direct sign E2 is running too low. Back off the AI before you blame your training.
- Fatigue in the first week — give it 7–10 days to reach steady state before judging; if it persists, you're over-suppressed.
Uncommon (dose-dependent or individual)#
- Worsened lipid profile — dropping HDL and rising LDL, compounded by the lipid hit AAS are already delivering. Mauras et al. documented estrogen suppression worsening lipid markers in men, which is why over-suppression matters (https://pubmed.ncbi.nlm.nih.gov/10902781/). Pull a lipid panel at week 4 of cycle; if HDL is tanking, lower the anastrozole dose, not the other way around.
- Mild ALT/AST elevation — mostly a concern stacked with orals. Check liver enzymes on the same draw as E2.
- Depressed mood / anhedonia — estradiol is neuroactive in men; crashing it can flatten affect. Reduce dose.
- Erectile dysfunction despite good total T — classic low-E2 ED. Confirm with sensitive E2, then cut or pause anastrozole.
- Rebound estrogen after abrupt discontinuation — aromatase activity recovers over ~5–7 days and E2 can overshoot. Taper off over 1–2 weeks at end of cycle rather than stopping cold.
"Estrogen suppression with anastrozole adversely affected lipid profiles and resulted in decreased HDL cholesterol, highlighting the importance of not over-suppressing estradiol." — Mauras et al., JCEM (2000)
Rare but serious#
- Bone density loss — chronic long-term over-suppression of E2 in men reduces BMD because estradiol, not testosterone, drives male bone turnover. Not a concern for blast-length use; is a concern for years of daily high-dose AI. Warning sign: stress fractures, unexplained bone pain. DEXA scan if running anastrozole long-term on TRT.
- Severe arthralgia — disabling joint pain from prolonged E2 deficiency. Stop and let E2 recover.
- Significant ALT/AST elevation (>3× ULN) — rare but reported. Stop the AI (and any orals) and retest.
- Allergic reaction — rash, angioedema, dyspnea. Discontinue immediately.
Hard contraindications#
- Pregnancy or possible pregnancy — Category X, teratogenic. Not relevant to male users but matters if a female partner has access.
- Non-aromatizing cycles — do NOT run anastrozole on tren-only, masteron-only, primo-only, or most SARM-only cycles. Endogenous T is already suppressed, so there's almost no substrate to aromatize; adding an AI drives E2 to zero. This is the single most common anastrozole mistake in the community.
- Already-crashed E2 — if sensitive E2 is <15 pg/mL or you have textbook crash symptoms, do not "push through." Stop the AI.
- Concurrent exemestane or other AI — pick one. Stacking AIs is E2-crash-by-committee.
- Severe hepatic impairment — metabolism is primarily hepatic; clearance is unpredictable.
Gender, fertility, and PCT considerations#
Women (AAS users): anastrozole is safe for women in the oncology sense (it's an FDA-approved breast cancer drug at 1 mg/day), but it is the wrong tool for women on AAS — the goal there is estrogen preservation, not suppression. Pre-menopausal women should not use anastrozole without oncology oversight.
Fertility (men): anastrozole is not contraceptive and at TRT-adjacent doses actually improves spermatogenesis in men with a poor T:E2 ratio by raising LH and FSH. Dias et al. showed co-administered anastrozole prolonged therapeutic testosterone and controlled E2 in pellet-treated men (https://pubmed.ncbi.nlm.nih.gov/24119010/). It's a reasonable tool in fertility-preservation protocols under a knowledgeable urologist.
PCT: anastrozole is generally not the right tool for PCT. Modern PCTs lean on SERMs (enclomiphene, clomid, nolva) because they restart LH/FSH without suppressing the estrogen signal that actually drives HPTA recovery. Short, tapered use of anastrozole can be justified to blunt a post-cycle estrogen rebound in the first 1–2 weeks after a heavy aromatizing blast, but running an AI through PCT works against what PCT is trying to accomplish. For established gyno, switch to raloxifene 60 mg/day or tamoxifen 20 mg/day — an AI alone won't regress fibrotic tissue.
Stack & combine
Multipliers applied when these compounds run together. Values > 1 indicate a bonus on that axis. Tap a partner to expand the mechanism.
| Partner | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| synergistic | ×1.18 | ×1.08 | ×1.05 | |
| synergistic | ×1.15 | ×1.08 | ×1.10 | |
| synergistic | ×1.12 | ×1.05 | ×1.08 | |
| synergistic | ×1.12 | ×1.10 | ×1.08 |
FAQ — Anastrozole
Where to buy
NextChems
Affiliate link — we may earn a commission at no cost to you.
- Anastrozole | Buy Anastrozole (Arimidex) 5 mg | NEXTCHEMSBuy Anastrozole
Research & citations
5 studies cited on this page.
Conclusion
Anastrozole is the go-to AI for dialing in estrogen on moderate-to-heavy aromatizing cycles, but overdoing it will wreck progress and mood just as fast as leaving E2 unchecked.
Key takeaways:
- Standard dose: 0.25–0.5 mg twice weekly, titrated to bloods and symptoms
- Always pair dosing with sensitive-assay E2 labs; avoid guessing or chasing a textbook number
- Only run anastrozole when cycling aromatizing AAS (testosterone, dbol); it is pointless and harmful on non-aromatizing stacks
- For early gyno flares, short-term 1 mg/day knockdown is paired best with a SERM like raloxifene or tamoxifen
- Do not combine with other strong estrogen antagonists (masteron, proviron, exemestane) unless you want to risk a full E2 crash
- Long half-life supports convenient 2×/wk dosing on injection days; pharma tabs are cheap and easy to split
Run anastrozole only when your stack and your bloodwork justify it, at the lowest effective dose. When dosed right, it prevents estrogenic sides without tanking your health, sex drive, or gains.